Articles
52 result(s) for 'Lecanemab' within Alzheimer's Research & Therapy
Page 1 of 2
-
Citation: Alzheimer's Research & Therapy 2022 14:70
-
Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Citation: Alzheimer's Research & Therapy 2024 16:159 -
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease
Lecanemab (BAN2401) is a humanized IgG1 monoclonal ... this trial, subjects were randomized to five lecanemab dose regimens or placebo. The primary efficacy ... of sensitivity analyses evaluating the consistency ...
Citation: Alzheimer's Research & Therapy 2022 14:182 -
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Lecanemab (BAN2401), an IgG1 monoclonal antibody, ... to assess 3 doses across 2 regimens of lecanemab versus placebo in early Alzheimer’s disease,...
Citation: Alzheimer's Research & Therapy 2021 13:80 -
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
Lecanemab, a humanized IgG1 monoclonal antibody that targets ... core and OLE) supporting the effectiveness of lecanemab.
Citation: Alzheimer's Research & Therapy 2022 14:191 -
Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (Aβ) ... to neurons than monomers ...
Citation: Alzheimer's Research & Therapy 2024 16:105 -
The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond
CLARITY-AD is an 18-month, double-blinded, placebo-controlled, phase 3 trial which examined the safety and efficacy of the anti-amyloid agent, lecanemab, in mild cognitive impairment and mild dementia due to Alzh...
Citation: Alzheimer's Research & Therapy 2024 16:37 -
Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts
In Alzheimer’s disease (AD), amyloid-β 1–42 (Aβ42) neurotoxicity stems mostly from its soluble oligomeric aggregates. Studies of such aggregates have been hampered by the lack of oligomer-specific research too...
Citation: Alzheimer's Research & Therapy 2022 14:196 -
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Clinical trials in Alzheimer’s disease (AD) had high failure rates for several reasons, including the lack of biological endpoints. Fluid-based biomarkers may present a solution to measure biologically relevan...
Citation: Alzheimer's Research & Therapy 2024 16:93 -
Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer’s disease
Brain-directed immunotherapy is a promising strategy to target amyloid-β (Aβ) deposits in Alzheimer’s disease (AD). In the present study, we compared the therapeutic efficacy of the Aβ protofibril targeting an...
Citation: Alzheimer's Research & Therapy 2023 15:90 -
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Citation: Alzheimer's Research & Therapy 2021 13:98 -
Impact of amyloid and tau positivity on longitudinal brain atrophy in cognitively normal individuals
Individuals on the preclinical Alzheimer's continuum, particularly those with both amyloid and tau positivity (A + T +), display a rapid cognitive decline and elevated disease progression risk. However, limite...
Citation: Alzheimer's Research & Therapy 2024 16:77 -
APP dyshomeostasis in the pathogenesis of Alzheimer’s disease: implications for current drug targets
The Amyloid precursor protein (APP) is a transmembrane glycoprotein from which amyloid-β (Aβ) peptides are generated after proteolytic cleavage. Aβ peptides are the main constituent of amyloid plaques in Alzhe...
Citation: Alzheimer's Research & Therapy 2024 16:144 -
Five-mer peptides prevent short-term spatial memory deficits in Aβ25-35-induced Alzheimer’s model mouse by suppressing Aβ25-35 aggregation and resolving its aggregate form
The development of drugs for Alzheimer’s disease (AD), which is related to the misfolding and aggregation of amyloid-β (Aβ), is high in demand due to the growing number of AD patients. In this study, we screen...
Citation: Alzheimer's Research & Therapy 2023 15:83 -
Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis
With the emergence of disease-modifying Alzheimer’s treatments, timely detection of early-stage disease is more important than ever, as the treatment will not be indicated for later stages. Contemporary popula...
Citation: Alzheimer's Research & Therapy 2023 15:128 -
Prediction of conversion from mild cognitive impairment to Alzheimer’s disease and simultaneous feature selection and grouping using Medicaid claim data
Due to the heterogeneity among patients with Mild Cognitive Impairment (MCI), it is critical to predict their risk of converting to Alzheimer’s disease (AD) early using routinely collected real-world data such...
Citation: Alzheimer's Research & Therapy 2024 16:54 -
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
Maximizing the efficiency to screen amyloid-positive individuals in asymptomatic and non-demented aged population using blood-based biomarkers is essential for future success of clinical trials in the early st...
Citation: Alzheimer's Research & Therapy 2024 16:115 -
Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists
Alzheimer’s disease (AD) is a major global health crisis in need of more effective therapies. However, difficult choices to optimize value-based care will need to be made. While identifying preferred therapeut...
Citation: Alzheimer's Research & Therapy 2023 15:60 -
Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study
The mismatch between the limited availability versus the high demand of participants who are in the pre-dementia phase of Alzheimer’s disease (AD) is a bottleneck for clinical studies in AD. Nevertheless, pote...
Citation: Alzheimer's Research & Therapy 2023 15:189 -
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial
NeuroEPO plus is a recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life due to its low sialic acid content. NeuroEPO plus prevents oxidative damage, neuroinflammation, ...
Citation: Alzheimer's Research & Therapy 2023 15:215 -
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
With the approval of disease-modifying treatments (DMTs) for early Alzheimer’s disease (AD), there is an increased need for efficient and non-invasive detection methods for cerebral amyloid-β (Aβ) pathology. C...
Citation: Alzheimer's Research & Therapy 2024 16:154 -
Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer’s disease
The clinical meaningfulness of the effects of recently approved disease-modifying treatments (DMT) in Alzheimer’s disease is under debate. Available evidence is limited to short-term effects on clinical rating...
Citation: Alzheimer's Research & Therapy 2024 16:48 -
Long-term normalization of calcineurin activity in model mice rescues Pin1 and attenuates Alzheimer’s phenotypes without blocking peripheral T cell IL-2 response
Current treatments for Alzheimer’s disease (AD) have largely failed to yield significant therapeutic benefits. Novel approaches are desperately needed to help address this immense public health issue. Data sug...
Citation: Alzheimer's Research & Therapy 2023 15:179 -
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer’s disease (AD). A...
Citation: Alzheimer's Research & Therapy 2022 14:178 -
Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: a randomized, controlled clinical trial
Evidence links lifestyle factors with Alzheimer’s disease (AD). We report the first randomized, controlled clinical trial to determine if intensive lifestyle changes may beneficially affect the progression of ...
Citation: Alzheimer's Research & Therapy 2024 16:122 -
Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous i...
Citation: Alzheimer's Research & Therapy 2023 15:170 -
Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease
Targeting brain insulin resistance (BIR) has become an attractive alternative to traditional therapeutic treatments for Alzheimer’s disease (AD). Incretin receptor agonists (IRAs), targeting either or both of ...
Citation: Alzheimer's Research & Therapy 2024 16:173 -
Perspectives and challenges in patient stratification in Alzheimer’s disease
Patient stratification is the division of a patient population into distinct subgroups based on the presence or absence of particular disease characteristics. As patient stratification can be used to account f...
Citation: Alzheimer's Research & Therapy 2022 14:112 -
Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum
Multimer detection system-oligomeric amyloid-β (MDS-OAβ) is a measure of plasma OAβ, which is associated with Alzheimer’s disease (AD) pathology. However, the relationship between MDS-OAβ and disease severity ...
Citation: Alzheimer's Research & Therapy 2024 16:55 -
Cancer research provides a model for advancing clinical trials in dementia in the era of disease-modifying Alzheimer’s-type dementia therapies
Dementia and cancer are multifactorial, widely-feared, age-associated clinical syndromes that are increasing in prevalence. There have been major breakthroughs in clinical cancer research leading to some effec...
Citation: Alzheimer's Research & Therapy 2024 16:184 -
Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer’s disease continuum: considerations for clinical trials
To enable successful inclusion of electroencephalography (EEG) outcome measures in Alzheimer’s disease (AD) clinical trials, we retrospectively mapped the progression of resting-state EEG measures over time in...
Citation: Alzheimer's Research & Therapy 2023 15:182 -
Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment
Recruiting to multi-site trials is challenging, particularly when striving to ensure the randomized sample is demographically representative of the larger disease-suffering population. While previous studies h...
Citation: Alzheimer's Research & Therapy 2023 15:88 -
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia
Disease-modifying treatments for Alzheimer’s disease highlight the need for early detection of cognitive decline. However, at present, most primary care providers do not perform routine cognitive testing, in p...
Citation: Alzheimer's Research & Therapy 2024 16:2 -
Feasibility and therapeutical potential of local intracerebral encapsulated cell biodelivery of BDNF to AppNL−G−F knock-in Alzheimer mice
Alzheimer’s disease (AD) is an age-related disease characterized by altered cognition, neuroinflammation, and neurodegeneration against which there is presently no effective cure. Brain-derived neurotrophic fa...
Citation: Alzheimer's Research & Therapy 2023 15:137 -
How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment — a bidding game experiment
To estimate the perceived value of additional testing with amyloid-PET in Euros in healthy participants acting as analogue patients with mild cognitive impairment (MCI).
Citation: Alzheimer's Research & Therapy 2023 15:208 -
Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review
Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which had primarily positive conclusions, were investigated. Results...
Citation: Alzheimer's Research & Therapy 2023 15:98 -
Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study
A large proportion of nursing home (NH) residents suffer from dementia and effects of conventional anti-dementia drugs on their health is poorly known. We aimed to investigate the associations between exposure...
Citation: Alzheimer's Research & Therapy 2024 16:117 -
A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3
Alzheimer’s disease (AD) is characterized by cognitive dysfunction and amyloid plaques composed of the amyloid-beta peptide (Aβ). APOE is the greatest genetic risk for AD with APOE4 increasing risk up to ~ 15-fol...
Citation: Alzheimer's Research & Therapy 2023 15:216 -
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study
Identifying individuals with mild cognitive impairment (MCI) who are likely to progress to Alzheimer’s disease and related dementia disorders (ADRD) would facilitate the development of individualized preventio...
Citation: Alzheimer's Research & Therapy 2023 15:211 -
Home-based transcranial alternating current stimulation (tACS) in Alzheimer’s disease: rationale and study design
Gamma (γ) brain oscillations are dysregulated in Alzheimer’s disease (AD) and can be modulated using transcranial alternating stimulation (tACS). In the present paper, we describe the rationale and design of a...
Citation: Alzheimer's Research & Therapy 2023 15:155 -
A metagenomic study of gut viral markers in amyloid-positive Alzheimer’s disease patients
Mounting evidence suggests the involvement of viruses in the development and treatment of Alzheimer’s disease (AD). However, there remains a significant research gap in metagenomic studies investigating the gu...
Citation: Alzheimer's Research & Therapy 2023 15:141 -
Pathophysiology characterization of Alzheimer’s disease in South China’s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)
The Guangdong-Hong Kong-Macao Greater-Bay-Area of South China has an 86 million population and faces a significant challenge of Alzheimer’s disease (AD). However, the characteristics and prevalence of AD in th...
Citation: Alzheimer's Research & Therapy 2024 16:84 -
Understanding machine learning applications in dementia research and clinical practice: a review for biomedical scientists and clinicians
Several (inter)national longitudinal dementia observational datasets encompassing demographic information, neuroimaging, biomarkers, neuropsychological evaluations, and muti-omics data, have ushered in a new e...
Citation: Alzheimer's Research & Therapy 2024 16:175 -
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
Citation: Alzheimer's Research & Therapy 2023 15:210 -
The cognitive effect of non-invasive brain stimulation combined with cognitive training in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis
Non-invasive brain stimulation (NIBS) combined with cognitive training (CT) may have shown some prospects on improving cognitive function in patients with Alzheimer’s disease (AD) and mild cognitive impairment...
Citation: Alzheimer's Research & Therapy 2024 16:140 -
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease
Hyperhomocysteinemia (HHcy) has been linked to development of Alzheimer’s disease (AD) neuropathologically characterized by the accumulation of amyloid β (Aβ). Microglia (MG) play a crucial role in uptake of A...
Citation: Alzheimer's Research & Therapy 2023 15:164 -
Blood–brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease
Aggregation of the amyloid-β (Aβ) peptide in the brain is one of the key pathological events in Alzheimer’s disease (AD). Reducing Aβ levels in the brain by enhancing its degradation is one possible strategy t...
Citation: Alzheimer's Research & Therapy 2022 14:180 -
Comparison of plasma soluble and extracellular vesicles-associated biomarkers in Alzheimer’s disease patients and cognitively normal individuals
Amyloid-β (Aβ) and tau are brain hallmarks of Alzheimer’s disease (AD), also present in blood as soluble biomarkers or encapsulated in extracellular vesicles (EVs). Our goal was to assess how soluble plasma bi...
Citation: Alzheimer's Research & Therapy 2024 16:141 -
Protein intake and episodic memory: the moderating role of the apolipoprotein E ε4 status
This study investigated the correlation between protein intake and Alzheimer’s disease (AD)-related cognitive decline, particularly in episodic memory, among older adults without dementia. Furthermore, we asse...
Citation: Alzheimer's Research & Therapy 2024 16:181 -
A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
Amyloid-β42 (Aβ42) aggregation consists of a complex chain of nucleation events producing soluble oligomeric intermediates, which are considered the major neurotoxic agents in Alzheimer’s disease (AD). Cerebral l...
Citation: Alzheimer's Research & Therapy 2024 16:13
Follow
- ISSN: 1758-9193 (electronic)